Seroatlas · Human Serome Atlas

ATP9A

Probable phospholipid-transporting ATPase IIA

Also known as: ATP9A_HUMAN, ATPIIA, KIAA0611

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
O75110
Gene
ATP9A
Ensembl
ENSG00000054793
Chromosome
20
Canonical length
1047 aa
Protein class
Enzymes, Predicted membrane proteins, Transporters

OverviewNCBI Gene

Enables protease binding activity. Involved in negative regulation of exosomal secretion; regulation of endocytic recycling; and regulation of retrograde transport, endosome to Golgi. Located in several cellular components, including endosome; perinuclear region of cytoplasm; and trans-Golgi network membrane. Implicated in neurodevelopmental disorder with poor growth and behavioral abnormalities. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

1047 residues, UniProt reviewed canonical sequence.

>O75110|ATP9A
     1  MTDNIPLQPV RQKKRMDSRP RAGCCEWLRC CGGGEARPRT VWLGHPEKRD QRYPRNVINN
    61  QKYNFFTFLP GVLFNQFKYF FNLYFLLLAC SQFVPEMRLG ALYTYWVPLG FVLAVTVIRE
   121  AVEEIRCYVR DKEVNSQVYS RLTARGTVKV KSSNIQVGDL IIVEKNQRVP ADMIFLRTSE
   181  KNGSCFLRTD QLDGETDWKL RLPVACTQRL PTAADLLQIR SYVYAEEPNI DIHNFVGTFT
   241  REDSDPPISE SLSIENTLWA GTVVASGTVV GVVLYTGREL RSVMNTSNPR SKIGLFDLEV
   301  NCLTKILFGA LVVVSLVMVA LQHFAGRWYL QIIRFLLLFS NIIPISLRVN LDMGKIVYSW
   361  VIRRDSKIPG TVVRSSTIPE QLGRISYLLT DKTGTLTQNE MIFKRLHLGT VAYGLDSMDE
   421  VQSHIFSIYT QQSQDPPAQK GPTLTTKVRR TMSSRVHEAV KAIALCHNVT PVYESNGVTD
   481  QAEAEKQYED SCRVYQASSP DEVALVQWTE SVGLTLVGRD QSSMQLRTPG DQILNFTILQ
   541  IFPFTYESKR MGIIVRDEST GEITFYMKGA DVVMAGIVQY NDWLEEECGN MAREGLRVLV
   601  VAKKSLAEEQ YQDFEARYVQ AKLSVHDRSL KVATVIESLE MEMELLCLTG VEDQLQADVR
   661  PTLETLRNAG IKVWMLTGDK LETATCTAKN AHLVTRNQDI HVFRLVTNRG EAHLELNAFR
   721  RKHDCALVIS GDSLEVCLKY YEYEFMELAC QCPAVVCCRC APTQKAQIVR LLQERTGKLT
   781  CAVGDGGNDV SMIQESDCGV GVEGKEGKQA SLAADFSITQ FKHLGRLLMV HGRNSYKRSA
   841  ALSQFVIHRS LCISTMQAVF SSVFYFASVP LYQGFLIIGY STIYTMFPVF SLVLDKDVKS
   901  EVAMLYPELY KDLLKGRPLS YKTFLIWVLI SIYQGSTIMY GALLLFESEF VHIVAISFTS
   961  LILTELLMVA LTIQTWHWLM TVAELLSLAC YIASLVFLHE FIDVYFIATL SFLWKVSVIT
  1021  LVSCLPLYVL KYLRRRFSPP SYSKLTS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against ATP9A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
10
Mean surface accessibility (rSASA)
0.25
Highest tissue expression
88 nTPM

Expression across tissuesHPA

Tissue

  • cerebral cortex: 88 nTPM
  • basal ganglia: 52 nTPM
  • cerebellum: 49 nTPM
  • hypothalamus: 44 nTPM
  • hippocampal formation: 41 nTPM
  • amygdala: 40 nTPM

Single-cell type

  • urothelial cells: 286 nCPM
  • adipocytes: 275 nCPM
  • pancreatic islet cells: 243 nCPM
  • salivary ionocytes: 220 nCPM
  • foveolar cells: 214 nCPM
  • brain excitatory neurons: 187 nCPM

Immune cell

  • basophil: 4.4 nTPM
  • NK-cell: 1 nTPM
  • total PBMC: 0.7 nTPM
  • gdT-cell: 0.3 nTPM
  • memory CD8 T-cell: 0.3 nTPM
  • intermediate monocyte: 0.1 nTPM

Brain region

  • cerebral cortex: 217 nTPM
  • basal ganglia: 208 nTPM
  • hippocampal formation: 200 nTPM
  • hypothalamus: 191 nTPM
  • midbrain: 189 nTPM
  • amygdala: 185 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about ATP9A.

Disease | AllUniProt

Conditions ATP9A is implicated in, by any mechanism.

Disease | GeneticClinVar

13 pathogenic / likely-pathogenic of 175 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.21
gnomAD pLI
1
gnomAD missense Z
4.15
DepMap mean gene effect
0
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 11% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of ATP9A in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads ATP9A as an antibody target. Whether an autoantibody or antibody against ATP9A could matter depends on whether native ATP9A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

ATP9A is annotated at the cell surface, where native ATP9A is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label ATP9A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/ATP9A. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...